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the expression of HCMV components and an angiogenesis marker, endocan, in 79
glioma specimens and 8 control brain samples. HCMV pp65 protein and DNA were
detected in 65.8% (52 of 79) and 54.4% (43 of 79) of glioma specimens, respectively.
The positive rate and expression levels of pp65 were significantly correlated with the
glioma grades. The endocan expression was detected in 78.5% (62 of 79) of glioma
specimens, and elevated endocan immunoreactivity was also significantly associ-
ated with high-grade glioma. The pp65 was predominantly detected and colocal-
ized with endocan in the cytoplasm of tumor cells. Importantly, there was a
significant positive correlation in detection rates between those 2 proteins. In control
samples, neither HCMV pp65 nor endocan expression was detected. Moreover, the
serum endocan levels in glioma patients were markedly higher than that in healthy
subjects. In in vitro study, HCMV infection induced the expression of interleukin 6 and
tumor necrosis factor-a in human glioblastoma U87 MG (U87) cells and human um-
bilical vein endothelial cells (HUVECs). Furthermore, elevated endocan levels were
also observed in HCMV-infected U87 cells and HUVECs and antiviral treatment with
ganciclovir reduced the endocan expression. These results suggest HCMV infection
leads to gliomaprogression throughanupregulation of endocanand the secretion of
inflammatory cytokines. Thus, anti-HCMV treatment may represent a potentially
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Glioma is the most common and aggressive primary
brain tumor that cannot be completely resected surgi-
cally. Among them, malignant glioma is associated
with high recurrence and high mortality rates. Patients
with glioblastoma multiforme (GBM), a form of malig-
nant glioma, currently have a median survival time of
less than 15 months. The etiology and pathogenesis of
glioma remain largely unclear. Genetic alterations due
to intrinsic or environmental factors are thought to be
involved in the initiation of glioma and its progression.1
Epidemiologic data have shown that viruses are the sec-
ond most important risk factor for cancer development
in humans.2 Several cancer types are known to have a
viral etiology and some viruses have been established
as cancer causing agents. For example, close associa-
tions between hepatitis B and C viruses and hepatic
cell carcinoma have been established; and certain types
of human papillomavirus have been demonstrated to
cause cervical cancer. However, there are other viruses
whose roles in oncogenesis are more controversial. For
instance, what is the role of the human cytomegalovirus
(HCMV) in the initiation and progression of glioma3?HCMV is a double-stranded DNA virus that belongs
to the herpesviridae family. It carries a large genome
which encodes approximately 200 proteins, including
immediate-early and pp65 proteins. pp65 is the most
abundant virion protein and a major component of the
dense bodies of noninfectious viral particles. Thus, the
expression levels of pp65 are often used as an important
indicator of HCMV infection. HCMV is prevalent in up
to 70%–90% of the general population, and it persists
for life long after primary infection. During initial infec-
tion or viral reactivation, HCMV can cause serious and
even fatal complications in fetuses or immunocompro-
mised individuals.
The role of HCMV in glioma was first noted in 2002
when Cobbs et al4 reported the presence of HCMV gene
products in 100% of the tested GBM samples compared
with none in the normal control tissues. This was
confirmed by several other groups recently.5,6 In
addition, anti-HCMV therapy with valganciclovir has
achieved promising results in GBM patients.7 In an
experimental model, perinatal cytomegalovirus infec-
tion promotes glioma progression in transgenic mice.8
However, conflict results had also been reported. In
some studies, no HCMV genes or proteins were de-
tected in glioma samples.9,10 These controversial
results raise uncertainty about the role of HCMV in
the pathogenesis of glioma. Is it a true pathogenic
element or simply a bystander factor?
Glioma growth has been demonstrated to be strongly
dependent on angiogenesis.11 The main factors indica-
tive of angiogenesis have been well established, and
all of which may have therapeutic implications. Early
antiangiogenesis therapy was considered a promising
tool for the treatment of glioma. Bevacizumab, a mono-
clonal antibody targeting vascular endothelial growth
factor (VEGF), is an important agent in the treatment
of recurrent glioma.12 However, treatment based on
this target has shown limited therapeutic effect on gli-
oma, mainly due to the drug resistance. In fact, bevaci-
zumab treatment for GBM only achieved 20%–40%
efficacy, and the 6-month progression-free survival
rate is only 30%–50%.13 Therefore, additional thera-
peutic targets need to be identified.
Many angiogenesis-related genes are potentially
involved in tumor growth. In our preliminary experi-
ments, levels of angiogenesis-related genes including
VEGF, angiogenin-1, angiogenin-2, and endocan in
HCMV-infected glioblastoma U87 MG (U87) cells
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Only the endocan gene was strongly induced and
maintained at high levels for a long time after
HCMV infection besides VEGF. Endocan was firstly
cloned from a human umbilical vein endothelial cells
(HUVECs) complementary DNA (cDNA) library in
1996. It is a secreted cysteine-rich dermatan sulfate
proteoglycan and considered to be an endothelial
cell-specific molecule.14 Endocan is primarily ex-
pressed in vascular endothelial cells (VECs) and nor-
mally maintained a stable low level in the blood of
healthy subjects. It is specifically secreted by VECs
in response to proinflammatory cytokines and proan-
giogenic factors.15,16 It has been suggested to
mediate cell proliferation and promote angiogenesis
and vascular remodeling in several tumor types.17
Many studies have indicated that endocan is overex-
pressed in patients with cancer, sepsis, obesity, or in-
flammatory conditions, and increased endocan in the
sera of cancer patients has been associated with
enhanced tumor invasiveness, metastasis, and recur-
rence.15 As a biomarker of neoangiogenesis, endocan
is also a signature of tumor progression when it is ex-
pressed by tumor cells.18 However, beyond its secre-
tion by stimulation of proinflammatory cytokines and
proangiogenic factors, the trigger of endocan overex-
pression in tumor is not well understood. Although
elevated expressions of HCMV components or endo-
can in glioma tissue have been reported,19,20 whether
there is an intrinsic link among HCMV infection,
endocan expression, and glioma pathogenesis has
never been examined.
In the present study, we investigated the association
between HCMV and glioma and whether endocan
expression provides a link between the two. Both
HCMV pp65, as an indicator of HCMV infection, and
endocan, a marker of angiogenesis, were detected at a
higher rate in glioma tissues than in controls. In addi-
tion, there was a significant positive correlation between
the expressions of HCMV pp65 and endocan. Further-
more, the expression of those 2 proteins increased
with the clinical grades of glioma. In in vitro studies,
increased expressions of interleukin (IL)-6 and tumor
necrosis factor (TNF)-a were observed in HCMV-
infected U87 cells and HUVECs, and elevated endocan
expression was detected in the same HCMV-infected
cells. In contrary, anti-HCMV treatment with ganciclo-
vir (GCV) significantly reduced the expression of endo-
can. Our results suggest that HCMV contributes to
glioma progression through an upregulation of endocan
and inflammatory cytokines. Hence, this study provides
insights into new therapeutic approaches for glioma by
targeting HCMVor endocan.MATERIAL AND METHODS
Patient data. Seventy-nine patients with glioma who
underwent surgical resection between January 2007
and September 2013 in Beijing Tiantan Hospital were
enrolled in our study. The histologic diagnosis was es-
tablished according to the 2007World Health Organiza-
tion classification guidelines and verified by 2
neuropathologists. Among the 79 glioma cases, there
were 43 (54.4%) high-grade glioma (HGG, grades III–
IV) and 36 (45.6%) low-grade glioma (LGG, grades
I–II). The patients included 48 (60.8%) men and 31
(39.2%) women, with an average age of
43.8 6 13.6 years (range: 8–78 years). The
male:female ratio in the enrolled patients was 1.5.
Eight control brain tissues were obtained from trauma
surgery (n 5 3) and autopsy (n 5 5) patients who had
died from noncentral nervous system diseases.
The clinical samples were immediately snap frozen
after the resection. For each sample, the percentage of
tumor cells was examined using a hematoxylin and
eosin-stained frozen section. Only samples that con-
sisted of more than 80% tumor cells were included in
the study. Peripheral blood samples were collected
from 47 glioma patients and 47 healthy controls. The
study was approved by the Institutional Review Board
of Beijing Tiantan Hospital, and written informed con-
sent was obtained from all patients.
Cell cultures and virus. Human brain glioblastoma
U87 MG cells (U87) were obtained from China Infra-
structure of Cell Line Resources and cultured in Dul-
becco’s modified Eagle’s medium (Gbico, Carlsbad,
Calif) supplemented with 10% fetal bovine serum
(FBS). HUVECs were purchased from KeyGen biotech
and grown in RPMI1640 with 10% FBS. MRC5 human
fibroblasts (CICR) were cultured in minimum essential
medium with 10% FBS and 1% non-essential amino
acid. The laboratory HCMV strain AD169, kindly pro-
vided by Dr. Q. Ruan, Shengjing Hospital, Chinese
Medical University, was propagated and titrated in
MRC5 cells. The virus was stored at 280C until use.
HCMV infection experiment in U87 cells and
HUVECs. For in vitro infection experiment, U87 cells
or HUVECs were infected with HCMV strain
AD169 at a multiplicity of infection of 3. Heat-
inactivated (65C for 30 minutes) HCMV was used
for mock infection. After incubation at 37C for
2 hours, the virus solution was removed and then the
cells were continued to culture until indicated times
when cells and the supernatants from mock- and
HCMV-infected groups were collected for the
detection of IL-6, TNF-a, and endocan levels.
Infection experiments were performed independently
for at least 3 times.
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S1878) on HCMV infection, cytotoxicity of GCV was
first measured using the 3-(4,5-dimethylthiazol-2-yl)-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich)
method. In brief, U87 cells or HUVECs were treated
with GCV at concentrations of 1, 10, 100, 200, 400,
600, and 800 mM at 37C for 6 days. During this period,
there was no significant cytotoxicity of GCV at
1400 mM to U87 cells or HUVECs.
Then inhibition of GCVat different doses on HCMV
replication was determined. Briefly, U87 cells or HU-
VECs were infected with HCMV (multiplicity of
infection 5 3) at 37C for 2 hours in the presence of
GCV at 25, 50, 100, 200, and 400 mM, respectively,
and then the virus was removed. After being washed,
the cells were kept in culture continuously. At 1, 2,
and 4 days post infection (dpi), cells and supernatants
were collected for the detection of HCMV US17 by
PCR. GCV at 25200 mM showed inhibitory effect on
HCMV replication; thus, 200 mM was determined as
work concentration to use on U87 cells and HUVECs.
Multiplex flow cytometry. The cytokines levels in su-
pernatants of cells with mock or HCMV infection
were quantified by AimPlex Human Inflammation
3-Plex assay kits (Beijing Quantobio, China)
according to the manufacturer’s instruction manual.
Briefly, antigen and capture antibody conjugated
beads were first incubated for 60 minutes, followed by
incubation for 30 minutes with biotinylated detection
antibodies, and finally incubation for 20 minutes with
streptavidin-PE. Fluorescence signals of the sample
beads were acquired by a flow cytometer (NovoCyte
D1040) and levels of the inflammatory factors were
analyzed with FCAP Array 3.0.
RNA extraction, cDNA synthesis, and real-time reverse
transcription-polymerasechain reaction. For determining
levels of endocan and HCMV US17 genes, total cellular
RNA was extracted from cells using the TRIzol reagent
(Ambion) according to the manufacturer’s instructions.
The concentration of RNAwas quantified using the Nano-
Drop2000c Spectrophotometer (NanoDrop Technolo-
gies). cDNAwas synthesized using 1 mg of total RNA as
the template and oligo dT as a primer, as described in
the manufacturer’s protocol for reverse transcription
(Promega). Fluorescence quantitative PCR instrument
(Applied Biosystems 7500 Fast Real-Time PCR
Systems, Life Technologies, Carlsbad, Calif) and a
GoTaq qPCR Master Mix (Promega) kit were used to
detect target gene expressions, and b-actin was used
as an internal reference. The sequences of specific
primers are as follows: US17, forward, 50-
GCGTGCTTTTTAGCCTCTGCA-30; reverse, 50-
AAAAGTTTGTGCCCCAACGG TA-30, endocan;forward, 50-CAGGCATGGATGGCATGAAG-30;
reverse, 50-CTGACTGG CAGTTGCAGGTCT C-30 and
b-actin, forward, 50-TGGCACCCAGCACAATGAA-30;
reverse, 50-CTAAGTCATAGTCCGCCTAGAAGCA-30.
The 22DDCT method was employed to determine the
relative expression of target genes normalized to b-actin.
The determination for each sample was repeated 3 times.
Western blot analysis. Cells were harvested and lysed
with ice cold RIPA buffer (Cell Signaling Technology)
with 1x protease inhibitor cocktail (Cell Signaling
Technology). Equivalent amounts of extract protein
(20 mg) were resolved in 10% sodium dodecyl sulfate-
polyacrylamide gels and electroblotted onto
polyvinylidene fluoride membranes (Millipore,
Billerica, Mass). The membranes were blocked and
incubated with mouse anti-endocan mAb (clone
MEP14; Lunginnov) and rabbit anti-b-actin (#4970,
Cell Signaling Technology) overnight at 4C. In the
HCMV-infected U87 cells experiment, the bands were
visualized using horseradish peroxidase (HRP)–
conjugated immunoglobulin G (IgG) secondary
antibodies and the SignalFire Elite ECL Reagent (Cell
Signaling Technology). In the HCMV-infected
HUVECs experiment, the bands were visualized using
goat anti-mouse and anti-rabbit IgG DyLight 800 and
680 secondary antibodies (Thermo Scientific),
followed by scanning using an Odyssey CLx infrared
imaging system (LI-COR Biosciences).
Immunohistochemistry (IHC). The brain tissue samples
were fixed with 4% paraformaldehyde and embedded in
paraffin. Tissue sections were subjected to immunostain-
ing for HCMV components and endocan. In brief, 6-mm
sections weremounted onto slides coated with 5%APES
(3-aminopropyltriethoxysilane), dried overnight at 56C,
deparaffinized in xylene and rehydrated through
descending graded alcohols to phosphate-buffered
saline (PBS, pH 7.4). Endogenous peroxidase activity
were blocked with 3% hydrogen peroxide for
10 minutes and nonspecific antibody binding sites and
then the slides were incubated with 1% bovine serum
albumin (in PBS) to block nonspecific antibody
binding sites. For antigen retrieval, slides were
immersed in 10 mmol/L sodium citrate buffer (pH 6.0;
ZLI-9064, Zhongshan Golden Bridge Bio Co., Ltd.,
China) and boiled 3 times for 10, 5, and 5 minutes,
respectively, in a microwave oven (800 W). After
being cooled to room temperature and washed with
PBS, the sections were incubated at 4C overnight
with the following antibodies: anti-pp65 (ab49214,
1:200, Abcam) or anti-endocan (ab56914, 1:300,
Abcam), followed by the addition of a secondary HRP-
conjugated goat anti-mouse antibody (PV9002,
Zhongshan Golden Bridge Bio Co., Ltd., China). The
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diaminobenzidine (DAB) as a chromogen. Once the
brown color was observed under a microscope, the
reaction was stopped by removing the DAB and
washing with dH2O. After counterstaining with
hematoxylin, the positive or negative staining was
independently evaluated by 2 investigators who were
blinded to the clinical data, according to the scoring
methodology described in the following section. The
negative controls were performed using phosphate
buffer instead of the primary antibody.
Double immunofluorescence staining. For double la-
beling of HCMV pp65 and endocan, the sections were
simultaneously incubated with mouse anti-HCMV
pp65 monoclonal Antibody (ab49214, 1:20, Abcam)
and goat anti-endocan polyclonal antibody (AF1810,
1:20, R&D) at 4C overnight, followed by incubation
with secondary antibody (Alexa Fluor 488-labeled
donkey anti-mouse IgG and Alexa Fluor 594-labeled
donkey anti-goat IgG, 1:1000 for both, Life
Technologies). The nucleus was stained with
40,6-diamidino-2-phenylindole (1:40, Sigma), and the
images were observed and taken under a microscope
(Olympus X-cite 120; Olympus, Japan).
In situ hybridization. For the detection of HCMV nu-
cleic acids in the brain sections, a digoxin-labeled
DNA probe specific for pp65 (50-GCTCTTCTTTTT
CGATATCGACTTGTTGCTGCAGCG-30), digoxin-
labeled Alu DNA probe (positive control), and insect
genomic DNA probe (negative control) were
purchased from Life Technologies. Before
hybridization, the sections (5-mm thick) were
deparaffinized, dehydrated, and incubated with 3%
hydrogen peroxide to block endogenous peroxidase
activity and followed by treatment with Proteinase K
at 37C for 25 minutes and then incubated with the
probes diluted using DIG Easy Hyb (11603558001,
Roche) and heated to 95C for 20 minutes in
Hybridization Oven (the UVP HL-2000 HybriLinker)
to denature any secondary structures. Hybridization
was performed at 37C overnight. After incubation
with mouse antidigoxin IgG, the reaction was
visualized by the addition of HRP-conjugated goat
anti-mouse IgG and DAB, and the images were
collected. The scoring methodology for positive
staining was equivalent to that used for IHC.
Scoring methodology of IHC and in situ
hybridization. The immunostaining results were evalu-
ated by a previously described scoring methodology.21,22
Positive cells were counted using image analysis
software (Image-Pro Plus 6.0; Media Cybernetics Inc.).
Cells showing yellow or brown particles in the
cytoplasm or nucleus were considered positive. The
sections were observed under 5 random high-powerfields, and 100 cells were counted per field. The
semiquantitative results were expressed as the
percentage of positive cells combined with a subjective
assessment of staining intensity. The staining intensity
was scored as 0 (colorless), 1 (light yellow), 2 (yellow
or brown), and 3 (dark brown); the percentages of
positive cells were denoted as 0 (,5%), 1(5%–25%), 2
(26%–50%), 3 (51%–75%), and 4 (.75%). The
multiplication of both scores was used to evaluate the
immunostaining results, as follows: overall scores of
#3, .3–6, and .6 were defined as negative, weakly
positive, and strongly positive, respectively.
Enzyme-linked immunosorbent assay for the
determination of endocan levels in patient serum and
cell supernatant. The endocan levels in serum samples
and cell supernatants were quantified using a sandwich
enzyme-linked immunosorbent assay. Briefly, a 96-well
plate was precoated with anti-endocan polyclonal
antibody (AF1810, R&D) at 4C overnight.
Subsequently, the serum and the cell supernatant
(100 mL/well) was added and incubated at 37C for
2 hours, followed by incubation with mouse anti-
endocan mAb (clone MEC 15; Lunginnov). The
bound endocan was detected using HRP-conjugated
goat anti-mouse IgG and o-phenylenediamine.
Absorbance was measured at 492 nm.
Statistical analysis. Statistical analysis was performed
using SPSS 17.0 (SPSS Inc.). The chi-square test and
Mann–Whitney U test were used to determine the
differences between the expressions of HCMV
components and endocan in different grade gliomas
and the correlations between pp65 and endocan
expressions. The Student t-test and one-way analysis of
variance were used to determine the differences in
serum endocan levels between glioma patients and
healthy subjects as well as the expression of endocan,
IL-6 and TNF-a between mock- and HCMV-infected
groups. P, 0.05 was considered statistically significant.
RESULTS
The expression of HCMV components in association with
gliomagrades. Of the 79 glioma specimens, 52 (65.8%)
showed positive immunoreactivity for pp65, which was
mainly detected in cytoplasm of tumor cells and occa-
sionally VECs as well (Fig 1, A). Of note, 93.0% (40
of 43) of the HGG and 33.3% (12 of 36) of the LGG
samples showed positive staining, respectively (Table
I). Strong positive staining of pp65 was observed in
25.6% (11 of 43) of the HGG, but only in 2.8% (1 of
36) of the LGG. In the semiquantitative analysis, there
were significant differences in detection rates and
expression levels of pp65 between the HGG and LGG
(Table I, P , 0.01). No pp65 expression was detected
in control brain tissues.
Fig 1. The expressions of HCMV components in glioma tissue of different grades. The pp65 protein and DNA
were detected by IHC (A) and ISH (B), respectively. Representative images were shown at low (upper panels
of A and B) or high (lower panels of A and B) magnification. The positive staining of pp65 was predominantly
observed in the cytoplasm of tumor cells. The strong intensity of the staining was closely associated with high
grades of glioma (gradesⅢ andⅣ). No expression of pp65 was detected in control brain tissues. Bar5 100 mm.
Table I. Summary of IHC and ISH data for HCMV components detection in glioma and control brain tissues
Brain samples Negative Weak positive Strong positive P value
pp65 protein
HGG (n 5 43)** 3 (7.0%) 29 (67.4%) 11 (25.6%)
LGG (n 5 36) 24 (66.7%) 11 (30.5%) 1 (2.8%) ,0.01
Control brain (n 5 8) 8 (100%) — —
pp65 DNA
HGG (n 5 43)* 15 (34.9%) 24 (55.8%) 4 (9.3%)
LGG (n 5 36) 21 (58.3%) 13 (36.1%) 2 (5.6%) ,0.05
Control brain (n 5 8) 8 (100%) — —
Abbreviations: HCMV, humancytomegalovirus;HGG, high-grade glioma; IHC, immunohistochemistry; ISH, in situ hybridization; LGG, low-grade
glioma.
Statistical analysis carried out using the Mann–Whitney U test is shown as *P , 0.05 and **P , 0.01, compared with LGG.
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(43 of 79) of the glioma samples: 65.1% (28 of 43) for
the HGG and 41.7% (15 of 36) for LGG (P , 0.05),respectively. Detection rates were significantly different
from each other (P , 0.05, Table I). The high levels of
pp65 DNA showed a trend of association with glioma
Table II. Summary of IHC data for endocan detection in glioma and control brain tissues
Brain samples Negative Weak positive Strong positive P value
HGG (n 5 43)** 1 (2.3%) 20 (46.5%) 22 (51.2%)
LGG (n 5 36) 16 (44.4%) 17 (47.2%) 3 (8.3%) ,0.01
Control brain (n 5 8) 8 (100%) — —
Abbreviations: HGG, high-grade glioma; IHC, immunohistochemistry; LGG, low-grade glioma.
Statistical analysis carried out using Mann–Whitney U test is shown as **P , 0.01, compared with LGG.
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tissues (Table I and Fig 1, B).
The expression of endocan in association with glioma
grades. As determined by IHC, there was little endocan
expression in the control brain tissue. However,
increased expression of endocan was detected in
78.5% (62 of 79) of glioma samples (Table II). The
positive staining located predominantly in the
cytoplasm of tumor cells and occasionally in VECs
(Fig 2, A). The positive rates of endocan
immunoreactivity were closely associated with the
glioma grades, with 97.7% (42 of 43) of HGG and
55.6% (20 of 36) of LGG showing positive
immunoreactivity, respectively (P , 0.01). Similarly,
high-intensity of endocan staining was observed in
51.2% (22 of 43) of the HGG but only in 8.3% (3/36)
of the LGG. There were significant differences in
detection rates and expression levels of endocan
between high-grade and LGG (P , 0.01; Table II).
Co-expression of pp65 and endocan in association with
gliomagrades. Colocalization of pp65 and endocan was
predominantly observed in the cytoplasm of the tumor
cells (Fig 2, B). Notably, of the 52 pp65-positive
glioma samples, 49 cases (94.2%) showed
coexpression of these 2 proteins, whereas of the 27
pp65-negative glioma cases, only 14 (51.9%) were
positive for endocan staining. By the chi-square test,
the elevated expression of endocan is positively
correlated with HCMV pp65 in 79 glioma cases
(P , 0.05, odds ratio 5 15.167, Table III), further
indicating an interaction between HCMVand endocan.
Furthermore, the mean endocan level of
19.27 6 10.87 ng/mL in sera of glioma patients was
significantly higher than that in healthy subjects
(10.60 6 7.54 ng/mL; P , 0.05, Fig 2, C).
HCMV infection upregulated the cytokine expression
levels of in U87 cells and HUVECs. The supernatant of
HCMV-infected U87 cells and HUVECs were
collected at 1, 2, and 4 dpi for determining levels of
cytokines by multiplex flow cytometry. As shown in
Fig 3, IL-6 and TNF-a showed a gradual increased
expression in U87 cells after HCMV infection. They
started to elevate at 2 dpi and reached a peak at 4 dpi.
In contrast, there was no obvious change in the
expression levels of IFN-g in U87 cells after theinfection (Fig 3, A and B). Meanwhile, similar trends
of change were also observed in HUVECs after the
infection. The expressions of IL-6 in HUVECs after
infection were much greater than those in U87 cells
(Fig 3, C and D). The expressions of TNF-a increased
significantly at 1 dpi, which is earlier than that seen in
U87 cells, and then plateaued at 2–4 dpi. There was
also no obvious change in IFN-g levels in HUVECs
after the infection. All changes of IL-6 and TNF-a
either in U87 cells or HUVECs after infection were
significantly different from that in mock infection
(**P , 0.01 or *P , 0.05).
HCMV infection upregulated endocan expression in
U87 cells and HUVECs and anti-HCMV treatment with
GCV reduced its expression. To test the effect of
HCMV infection on endocan expression, HCMV-
infected U87 cells and supernatant were collected at
indicated time points (1, 2, and 4 dpi). As shown in Fig
4, A, gradually elevated levels of HCMV US17 gene
were observed at different time points, indicating
productive infection. Meanwhile, the levels of endocan
mRNA and protein increased with the progress of
infection (Fig 4). At 1 dpi, the level of endocan mRNA
increased in HCMV-infected U87 cells, and then
gradually elevated until 4 dpi. They are significantly
different from that in mock groups (P , 0.01 for each
time point, Fig 4, B). Consistently, protein levels of
endocan in U87 cells and supernatant also gradually
increased: there were no obvious changes at 1 dpi, then
markedly increased, and finally reached peak levels at
4 dpi (Fig 4, C and D). There were significantly
differences between HCMVand mock infection groups
(P , 0.01 for 2 and 4 dpi). As expected, treatment
with GCV reduced the levels of HCMV US17 gene
expression in U87 cells, indicating an effectively
inhibitory effect on HCMV replication (Fig 4, A).
Accordingly, GCV treatment decreased levels of
endocan mRNA and protein in U87 cells and
supernatant (Fig 4, B–D), indicating that treatment
with GCV could inhibit the generation of endocan
induced by HCMV infection in U87 cells.
Similar results were also observed in HCMV-infected
HUVECs (Fig 5). Gradually elevated levels of HCMV
US17 gene were observed (Fig 5, A), accompanied by
gradually increased levels of endocan mRNA and
Fig 2. The expressions of endocan in tissues from glioma patients. A, The expressions of endocan in glioma tis-
sues of different grades were detected by IHC. Representative images of endocan expressions were shown at low
(upper panels) and high (low panels) magnification, respectively. The endocan immunoreactivity was mainly
observed in the cytoplasm of tumor cells. The elevated expression of endocan was significantly associated with
high grades of glioma (gradesⅢ andⅣ). There was no detectable expression of endocan in control brain tissues.
Bar5 100 mm.B, A section of glioma tissuewas processed for double immunofluorescent stainingwith antibodies
against pp65 and endocan. The colocalization (arrow) of these 2 proteins was mainly observed in the cytoplasm of
tumor cells (merge). The nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI). Bar5 100 mm.
C, The concentrations of endocan in the sera of glioma patients (n5 47, 19.276 10.87 ng/mL) and healthy sub-
jects (n5 47, 7.666 4.20 ng/mL)were determined by ELISA. *P, 0.05 versus healthy subjects as determined by
the Student t-test. ELISA, enzyme-linked immunosorbent assay.
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They were significantly different from that in mock
infection (P , 0.05, each value for each time point).
Accordingly, endocan levels in the supernatant also
obviously increased and gradually reached to peak
value at 4 dpi, it is also significantly different fromthat in mock infection (P , 0.01, Fig 5, D). Of note,
treatment with GCV inhibited significantly HCMV
replication and also significantly reduced endocan
expression (Fig 5). Taken together, our results suggest
a close association between HCMV infection and endo-
can expression in U87 cells and HUVECs.
Table III. Analysis on association between HCMV
pp65 and endocan expression in glioma tissue
Group Endocan(2) Endocan(1)
HCMV pp65(1; n5 52)* 3 (5.8%) 49 (94.2%)
HCMV pp65(2; n 5 27) 13 (48.1%) 14 (51.9%)
Abbreviation: HCMV, human cytomegalovirus.
Statistical analysis carried out using the c2 test is shown as *P, 0.05,
odds ratio 5 15.167.
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HCMV infection is closely associated with the
progression of glioma. Glioma accounts for approxi-
mately 30% of all brain and central nervous system tu-
mors and 80% of all malignant brain tumors,23 but its
etiology remains largely unknown. Recently, the
causal relationship between viral infections and
human cancers has become a common theme. HCMV
persistently infects 70%–90% of the normal
population, and its components were detected in
glioma tissue in several previous reports. However, its
role in the pathogenesis of glioma remains
controversial.24,25 In our study, elevated expressions of
HCMV pp65 protein and DNA, as an indicator of
HCMV infection, were discovered in glioma tissue,
and high detection rate and expression levels closely
associated with glioma grades, suggesting a clear
correlation between the expression of HCMV gene
products and glioma progression. In addition,
compared with pp65 protein, the detection rate for
pp65 DNA was relatively low, which is possibly
owing to the low copy numbers of viral DNA or the
fragmented, discontinuous viral genomes in glioma
tissues.9,20,26-28
Our results are consistent with those of several previ-
ous reports.9,20,26-28 Bhattacharjee et al29 discovered ev-
idence for the presence of cancer-associated pp65
genotypes in GBM tissue. Mitchell et al6 showed that
HCMV pp65 was detectable in 91% of GBM tissues
and that HCMV DNA could be detected in the periph-
eral blood of 80% of GBM patients. Further, Lucas
et al30 found that the expression rate of HCMV pp65
was 51% in 49 GBM tumors. These results from afore-
mentioned studies suggest a linkage between the pres-
ence of HCMV gene products and glioma progression.
Other than being in agreement with previous studies,
our results showed a positive correlation between the
presence of HCMV components and glioma grades,
therefore suggesting an active role of HCMV infection
in the progression of glioma.
However, there were also inconsistent reports
regarding HCMV and glioma. Some research groups
did not detect the expression of any HCMV componentsin glioma tissue9,27,28; whereas another group found no
correlations between the expression level of HCMV
gene products and glioma prognosis despite the
presence of HCMV components in glioma tissue.5 We
cannot explain the cause of discrepancy among these
studies, but epidemiologic variations, different study
populations, varied sample preparation, and divergent
detection techniques may have some influences.
Furthermore, no one could isolate viable virus from
glioblastoma samples so far. The reason related to this
issue remains unclear, and it may due to characteristics
of HCMV infections. Like other human herpes viruses,
the complete genome of HCMV reserves in host cells
after primary infection and does not produce infectious
viral particles at the latent state. However, at the special
conditions such as overwork, illness and immunocom-
promise, and so forth, the latent viral genome has the
potential to produce virus (reactivation) and/or cause
some clinical signs (recurrence). Thus, it is difficult to
isolate viable virus generally, but existence of viral an-
tigen and genome can be detected and they may reflect
the infection. Their amount may closely associate with
the viral replication repeatedly, further link to develop-
ment of the disease.
Endocan expression is closely associated with the
progression of glioma. Recently, endocan, an accurate
marker of VEC activation, has emerged as a promising
biomarker of vascular growth and angiogenesis in the
progression of several cancers,31-35 but there is limited
information regarding relationship between endocan
and glioma. In this study, high detection rates and
elevated expression of endocan were found to be
positively correlated with glioma grades, indicating a
role of endocan in glioma progression. In agreement
with a previous study in which upregulated endocan
expression was observed in glioma tissue,19 our
results suggest that there is a close link between
endocan and glioma and that endocan may be a viable
tissue-based biomarker. The molecular basis for this
association is not known, but endocan has been shown
to bind hepatocyte growth factor-scatter factor (HGF-
SF) and enhance the HGF-SF mediated mitogenic
effect in human epithelial cells.36 In many tumors,
HGF-SF acts as a stroma-derived factor that binds to
its receptor MET to promote proliferation, invasion,
and metastasis of cancer cells.37 In glioma, HGF/MET
signaling promotes the proliferation of glioma cells
via upregulation of Cox-2 expression and
prostaglandin E2 production.38 Taken together, it is
possible that endocan secreted from glioma cells can
enhance the effect of HGF/SF on the growth of glioma.
Accordingly, the serum endocan levels increased
significantly in glioma patients compared with that in
healthy subjects in our study. It has been reported that
Fig 3. The change of cytokine levels in the supernatant of human glioblastoma cell line U87 MG (U87) cells and
human umbilical vein endothelial cells (HUVECs) after HCMV infection.A, The levels of IL-6, TNF-a, IFN-g in
the supernatant of HCMV-infected U87 cells at 1, 2, and 4 days post infection (dpi) were detected via multiplex
flow cytometry. Each experiment was repeated at least 3 times. **P, 0.01, *P, 0.05 versus mock group as deter-
mined by the one-way analysis of variance. B, Representative flow cytometry scatter plot of the cytokines in
HCMV-infected U87 cells at 1, 2, and 4 dpi. Red cluster (upper): IFN-g; green cluster (middle): IL-6; red cluster:
(lower) TNF-a. C, The levels of IL-6, TNF-a, IFN-g in the supernatant of the cytokines in HCMV-infected HU-
VECs at 1, 2, and 4 dpi were detected via multiplex flow cytometry. Each experiment was repeated at least 3 times.
**P, 0.01, *P, 0.05 versus mock group as determined by the one-way analysis of variance. D, Representative
flow cytometry scatter plot of HCMV-infected HUVECs at 1, 2, and 4 dpi. Red cluster (upper): IFN-g; green clus-
ter(middle): IL-6; and red cluster: (lower) TNF-a. dpi, days post infection; IL-6, interleukin-6; IFN-g, interferon
gamma; TNF-a, tumor necrosis factor; PE-H, phycoerythrin height; APC-H, allophycocyanin height. (For inter-
pretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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Fig 4. The endocan expression was upregulated by HCMV infection in human glioblastoma cell line U87 MG
(U87) cells and reduced by treatment of infected cells with ganciclovir (GCV). A, Real-time PCR analysis of
HCMV US17 gene expression levels in HCMV-infected U87 cells at 1, 2, and 4 dpi. The treatment with GCV
markedly decreased US17 gene expression. B, Real-time PCR analysis of endocan mRNA levels in HCMV-
infected U87 cells at 1, 2, and 4 dpi. HCMV infection upregulated endocan mRNA levels and GCV treatment
reduced them. C, The endocan expression in U87 cells or HCMV-infected U87 cells was analyzed by Western
blot. HCMV infection upregulated endocan expression at 1, 2, and 4 dpi and GCV treatment reduced its levels.
Upper panel: Representative image of endocan expression in HCMV-infected U87 cells with or without GCV
treatment. b-actin was used as a loading control. Lower panel: a densitometric analysis of the Western blot results
(n5 3). D, The secreted levels of endocan in the supernatant of HCMV-infected U87 cells at 1, 2, and 4 dpi were
determined by ELISA. All experiments were performed more than 3 times each. Values represent means 6 SD
from at least 3 independent experiments. **P , 0.01, *P , 0.05 versus mock group as determined by the one-
way analysis of variance. ELISA, enzyme-linked immunosorbent assay; GCV, ganciclovir; dpi, days post infec-
tion; mRNA, messenger RNA.
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serum of patients with several other types of cancers,
including bladder cancer, acute myeloid leukemia, and
clear cell renal carcinoma,39-41 suggesting that the
serum endocan level may represent a promising
blood-based biomarker for the auxiliary diagnosis of
glioma, as well as of other cancers. Unfortunately,
because of the limited number of blood samples avail-
able, we could not further analyze the correlation be-
tween the serum endocan levels and glioma grades orcompare the expression levels of endocan in the serum
and glioma tissues in a paired fashion. Therefore,
further studies with more samples are needed to clarify
this association.
HCMV may be involved in glioma progression via
interaction with endocan and cytokines. A consensus is
gradually emerging in that HCMVantigens exist in gli-
oma tissues.3 However, possible mechanisms of
interaction between HCMV infection and host cells
have yet to be fully elucidated. Several studies have
Fig 5. The endocan expression was upregulated by HCMV infection in human umbilical vein endothelial cells
(HUVECs) and reduced by treatment of infected cells with ganciclovir (GCV). A, Real-time PCR analysis of
HCMV US17 gene levels in HCMV-infected HUVECs at 1, 2, and 4 dpi. The treatment with GCV markedly
decreased US17 gene relative expression. B, Real-time PCR analysis of endocan mRNA levels in HCMV-
infected HUVECs at 1, 2, and 4 dpi. HCMV infection upregulated endocan mRNA levels and GCV treatment
reduced them. C, The endocan expression in HUVECs or HCMV-infected HUVECs was analyzed by Western
blot. HCMV infection upregulated endocan expression at 1, 2, and 4 dpi and GCV treatment reduced its levels.
Upper panel: representative image of endocan expression in HCMV-infected HUVECs with or without GCV treat-
ment. b-actin was used as a loading control. Lower panel: a densitometric analysis of the Western blot results
(n5 3).D, the secreted levels of endocan in supernatant of HCMV-infected HUVECs at 1, 2, and 4 dpi were deter-
mined by ELISA. All experiments were performed more than 3 times each. Values represent means6 SD from at
least 3 independent experiments. **P, 0.01, *P, 0.05 versus mock group as determined by the one-way anal-
ysis of variance. ELISA, enzyme-linked immunosorbent assay; GCV, ganciclovir; dpi, days post infection;
mRNA, messenger RNA.
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signaling pathways via the expression of HCMV gene
products, thereby promoting angiogenesis and tumor
invasion.42 The factors triggering overexpression of
endocan in glioma tissue are not known, but
colocalization of pp65 and endocan was observed inthis study and the expressions of these 2 proteins were
highly correlated (Table II). Moreover, increased
levels of IL-6 and TNF-a, which could be responsible
for endocan’s biological activities and angiogenesis,43
were observed in HCMV-infected U87 cells and
HUVECs while IFN-g, which inhibit endocan
Translational Research
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possible role of cytokines in endocan expression.
Importantly, in vitro study showed that HCMV
infection could obviously elevate the expression of
endocan in U87 cells and HUVECs and anti-HCMV
with GCV inhibited this process, strongly indicating a
possible role of HCMV infection in the upregulation
of endocan. Furthermore, it has been reported that
mRNA expression of endocan in VECs is sensitive to
angiogenic growth factors and inflammatory
cytokines14,32; the direct interaction between dermatan
sulphate chain of endocan and cytokines enhances
endocan’s biological activities. Consistent with earlier
observations, our results suggest that HCMV may
enhance indirectly endocan expression via regulating
VEGF and cytokines such as TNF-a and IL-6, which
then interact with and activate endocan, and thereby
facilitate glioma progression.
In addition, HCMV-encoded proteins are thought to
be involved in the induction of endocan through the acti-
vation or inhibition of cellular signaling pathways. It
has been reported that HCMV-encoded chemokine re-
ceptor US28, a viral G protein coupled receptor, acti-
vates the IL-6–STAT3 (signal transducers and
activators of transcription 3) proliferative signaling
axis through activation of the transcription factor nu-
clear factor kB (NF-kB)44 and the consequent produc-
tion of cytokines, which contribute to expression and
activities of endocan. Moreover, it has been shown
that an upregulation of endocan by Epstein-Barr virus
latent membrane protein 1 was mediated through the
latent membrane protein 1–activated NF-kB, mitogen-
activated protein kinase (MEK)- extracellular signal-
regulated kinases, and c-Jun NH2-terminal kinase
signaling pathways.45 HCMV pp71 has been demon-
strated to induce a proinflammatory response via activa-
tion of NF-kB signaling in human GBM.46 Binding of
HCMV glycoproteins to platelet-derived growth factor
receptors or virus coreceptors, including integrins and
toll-like receptor 2, can induce c-Jun NH2-terminal ki-
nase pathway.47 However, further studies are needed to
clarify which HCMV-encoded protein is regulating en-
docan expression and what mechanism is involved in
this process.
In summary, we have demonstrated that elevated ex-
pressions of HCMV pp65 and endocan are closely
correlated with glioma grades. Interestingly, coexpres-
sion of HCMV pp65 and endocan was observed in gli-
oma tissues, and there was a significant correlation
between the intensity of their detection. In vitro study
showed increased levels of IL-6 and TNF-a in
HCMV-infected U87 cells and HUVECs. Treatment
with GCV could inhibit HCMV-induced endocan over
expression. To our knowledge, this is the first study toreveal a novel link between HCMV infection and endo-
can expression in glioma. Further research is needed to
clarify how HCMV regulates the expression of endocan
and consequently contributes to the pathogenesis of gli-
oma, and thus identifying new therapeutic strategies.
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